Plasma donations are used to manufacture life-sustaining therapies for people with rare diseases, immune deficiencies, bleeding disorders, and other chronic conditions. For many of these patients, plasma-derived treatments are the only option available. Plasma is also transfused directly to trauma and burn victims to support blood clotting and prevent shock.
What makes plasma so valuable is that it contains hundreds of proteins, each with a specific function. After donation, plasma is separated into these individual components through a manufacturing process called fractionation, and each component becomes the basis for a different medicine. A single donation contributes a small amount to what are often enormous treatment needs: treating one person with hemophilia for a year requires roughly 1,200 plasma donations.
Immune Deficiency Treatments
The largest category of plasma-derived medicine is immunoglobulin therapy, which delivers concentrated antibodies to people whose immune systems can’t produce enough on their own. People with primary immunodeficiency disorders are missing key infection-fighting proteins, leaving them vulnerable to repeated, severe infections. Regular infusions of immunoglobulin collected and purified from donated plasma give these patients a functional immune defense they can’t build themselves.
Immunoglobulin therapy is also used to treat several autoimmune and neurological conditions where the immune system attacks the body’s own tissues. These include chronic inflammatory demyelinating polyneuropathy (a nerve disorder that causes progressive weakness), Kawasaki disease in children, immune thrombocytopenic purpura (where the body destroys its own platelets), and myasthenia gravis (which causes severe muscle weakness). The demand is substantial: 130 donations are needed to treat one person with primary immunodeficiency for a single year, and 465 donations for one year of treatment for chronic inflammatory demyelinating polyneuropathy.
Bleeding and Clotting Disorders
People with hemophilia lack specific proteins that allow blood to clot normally. Without treatment, even minor injuries can cause dangerous, prolonged bleeding. Plasma-derived clotting factor concentrates replace the missing protein directly. Plasma from many donors is pooled, processed to isolate the clotting factors, freeze-dried, and then tested and treated to eliminate potential viruses before packaging.
Hemophilia A (missing factor VIII) and hemophilia B (missing factor IX) are both treated this way, though recombinant (lab-made) versions of these clotting factors also exist. Hemophilia requires an enormous volume of donated plasma: approximately 1,200 individual donations to treat a single patient for one year. Other, rarer bleeding and clotting disorders also depend on plasma-derived therapies, including Von Willebrand disease and antithrombin III deficiency.
Lung Disease From Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency is a genetic condition where the body doesn’t produce enough of a protein that protects the lungs. Without it, lung tissue breaks down over time, leading to emphysema that can appear unusually early in life. The primary treatment is augmentation therapy: purified alpha-1 antitrypsin protein collected from blood donors is delivered through an IV infusion on a regular schedule.
This therapy can’t reverse lung damage that has already occurred, but it can slow the progression of emphysema by restoring protective protein levels. It also doesn’t prevent liver damage, which is another complication of the condition. Because patients need ongoing infusions, the plasma demand is high. It takes about 900 donations to supply one person’s treatment for a year.
Trauma, Burns, and Surgical Care
Plasma serves a more immediate role in emergency medicine. Trauma patients who have lost significant blood volume receive plasma transfusions to restore clotting ability and maintain blood pressure. Burn victims, whose damaged skin allows massive fluid loss, also receive plasma to help stabilize blood volume and prevent shock. In these situations, plasma is often transfused directly rather than processed into a specific protein product.
Albumin, the most abundant protein in plasma, plays a central role here. It helps maintain the pressure that keeps fluid inside blood vessels. When albumin levels drop after severe injury or surgery, fluid leaks into surrounding tissues, causing dangerous swelling and circulatory collapse. Albumin derived from donated plasma has been used in clinical settings since the 1940s, when the original fractionation process was developed at Harvard.
Protecting Pregnancies With Rh Incompatibility
When a pregnant person has Rh-negative blood and carries a baby with Rh-positive blood, their immune system can recognize the baby’s blood cells as foreign and mount an attack. This condition, called Rh sensitization, can cause serious harm to the baby, including anemia and organ damage. A plasma-derived treatment prevents this by suppressing the mother’s immune response to the baby’s Rh-positive cells before sensitization occurs.
This treatment is manufactured from plasma collected from Rh-negative donors who have been immunized with Rh-positive red blood cells, producing the specific antibodies needed. It’s given around 26 to 28 weeks of pregnancy and again after delivery. It’s also administered after any event that might cause the baby’s blood to mix with the mother’s, such as amniocentesis, abdominal trauma, or pregnancy loss at any stage. A single dose contains enough antibody to neutralize a small but clinically significant volume of Rh-positive blood cells.
Infectious Disease Treatments
Plasma is the source material for specific immune globulin products that treat tetanus and rabies. These work similarly to general immunoglobulin therapy but contain high concentrations of antibodies targeted at a single pathogen. When someone is exposed to tetanus or rabies and needs immediate protection, these plasma-derived products provide ready-made antibodies while the person’s own immune system catches up.
During the COVID-19 pandemic, convalescent plasma (collected from people who had recovered from the virus) was used as a treatment, particularly for patients with compromised immune systems. The FDA continues to provide guidelines for its use in immunosuppressed patients who can’t mount an adequate immune response on their own, recognizing that the virus still poses serious risks for this population.
Why So Many Donations Are Needed
The gap between supply and demand for plasma is driven by simple math. Each donation yields a relatively small amount of any single protein, and patients with chronic conditions need treatment continuously, often for life. Here’s how the numbers break down for annual treatment of one patient:
- Primary immunodeficiency: 130 donations
- Chronic inflammatory demyelinating polyneuropathy: 465 donations
- Alpha-1 antitrypsin deficiency: 900 donations
- Hemophilia: 1,200 donations
These figures reflect the intensive processing involved. Plasma from many donors is pooled and then separated into its component proteins through fractionation, a process that combines chemical precipitation with advanced purification techniques and multiple rounds of virus safety treatment. The global industry still relies on a version of this process originally developed in the 1940s, refined with modern chromatography and safety measures. From collection to finished medicine, the timeline is long, which means today’s donations won’t reach patients for months.